Skip to main content
Medical information Clinical review pending

Genetic Testing

Prenatal Delta Beta Thalassaemia Mutation Screening

Prenatal Delta Beta Thalassaemia Mutation Screening identifies thalassaemia mutations in expectant mothers, aiding in early detection and management of potential genetic disorders in the fetus.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Amniotic fluid, Chorionic villi, or Peripheral blood.
Results
Typically 5-6 days. Confirm with the laboratory before booking.
Preparation
Confirm with the laboratory before booking. A doctor’s prescription is required for this test, except in cases of surgery, pregnancy, or travel abroad.
Test priceKSh 15,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Prenatal Delta Beta Thalassaemia Mutation Screening test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Expectant mothers with a family history of thalassaemia
  • ✓Individuals from populations with a higher prevalence of thalassaemia
  • ✓Previous pregnancy affected by genetic disorders
  • ✓Screening during prenatal care for at-risk individuals
02

In plain language

What this test helps you understand

This test helps identify the presence of specific genetic mutations associated with Delta Beta Thalassaemia in a fetus, allowing for early diagnosis and management planning during pregnancy.
The Prenatal Delta Beta Thalassaemia Mutation Screening is a vital genetic test designed for expectant mothers to detect thalassaemia mutations. This test plays a crucial role in prenatal care, allowing for early identification of potential genetic disorders that could affect the fetus. Understanding the genetic makeup is essential for informed decision-making and management during pregnancy.

This screening test detects specific mutations associated with Delta Beta Thalassaemia, a genetic blood disorder. It analyzes genetic material from samples like amniotic fluid, chorionic villi, or peripheral blood to identify abnormalities that may pose a risk to the developing fetus.

Expectant mothers, especially those with a family history of thalassaemia or individuals from high-risk populations, should consider this test. Other factors that may warrant testing include a previous pregnancy affected by genetic disorders or an ethnic background associated with higher thalassaemia prevalence.

The Prenatal Delta Beta Thalassaemia Mutation Screening offers significant benefits, including early detection of genetic disorders, informed decision-making regarding pregnancy management, peace of mind for expectant parents, and access to specialized care and support if needed.

Results are typically available within 5-6 days. It is essential to consult with your healthcare provider to interpret the results accurately and discuss the next steps based on the findings.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. A doctor’s prescription is required for this test, except in cases of surgery, pregnancy, or travel abroad.
SampleAmniotic fluid, Chorionic villi, or Peripheral blood.
MethodologyConfirm with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This is a screening test and may not detect all possible thalassaemia mutations. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Delta Beta Thalassaemia is a genetic blood disorder affecting haemoglobin production. This test screens for mutations associated with it.
Expectant mothers with a family history of thalassaemia, those from high-risk ethnic groups, or those advised by their doctor should consider this test.
Yes, a doctor’s prescription is required for this test, except in cases of surgery, pregnancy, or travel abroad.
Results are typically available within 5-6 days. Your healthcare provider will interpret the results with you.
The test can be performed using amniotic fluid, chorionic villi, or peripheral blood.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp